Global Platelet Rich Plasma Therapy Market by Type (Pure Platelet-rich Plasma, Platelet-rich Fibrin), Application (Orthopedics, Dermatology, Cosmetology, Rheumatology, Ophthalmology), End User (Hospitals and Clinics, Research Institutes)?Forecast to 2028
The global platelet rich plasma (PRP) therapy market is expected to grow at a CAGR of 12.2% during the forecast period to reach $882.5 million by 2028.

Following a thorough secondary and primary research and in-depth analysis of the market scenario, the report discusses key industry drivers, restraints, challenges, and opportunities.

The growth of this market is mainly attributed to factors such as the advantages offered by PRP treatment, increasing awareness toward PRP therapies, rising prevalence of musculoskeletal, sports, & orthopedic injuries, and the growing number of cosmetic procedures worldwide.

In addition, increasing PRP treatments and advancing healthcare in emerging economies are expected to offer significant growth opportunities for platelet rich plasma therapy providers.

However, the availability of alternatives for PRP treatment and side-effects associated with PRP is expected to restrain the growth of the platelet rich plasma therapy market to some extent during the forecast period. Also, the stringent regulatory framework for PRP use is the major challenging factor observed in this market.

Based on type, the global platelet rich plasma therapy market is segmented into pure PRP, leukocyte–rich PRP, pure platelet-rich fibrin, and leukocyte & platelet rich fibrin. In 2021, the pure PRP segment is estimated to account for the largest share of the global platelet rich plasma therapy market. Pure PRP is advantageous over conventional PRP as it undergoes a two-step concentration process that eliminates red blood cells and neutrophils. Thus, the advantages offered by pure PRP treatment over other pain-relieving and cosmetic treatments are expected to augment the segment’s growth during the coming years.

Based on application, the platelet rich plasma therapy market is segmented into orthopedics & traumatology, rheumatology, dermatology and cosmetology, ophthalmology, stomatology and odontology, and other applications. In 2021, the orthopedics and traumatology segment is estimated to account for the largest share of the global platelet rich plasma therapy market. The increasing number of patients suffering from musculoskeletal disorders and increasing recommendation of PRP therapy as a parallel treatment of various disorders such as fractures and chronic pain is expected to drive the demand for PRP for orthopedics and traumatology application in the market.

Based on end user, the global platelet rich plasma therapy market is segmented into hospitals & clinics and research institutes. In 2021, the hospitals & clinics segment is estimated to account for a larger share of the global platelet rich plasma therapy market. The large share of this segment is attributed to the usage of platelet rich plasma therapy by hospitals and clinics for pain management, regenerative medicines, joints & bone surgeries, cosmetic enhancements, hair growth, and sports injuries. PRP treatments are mostly applied to manage accidents and trauma, infectious diseases, orthopedic treatments, cosmetics, dermatology, and hair growth & transplant.

An in-depth analysis of the geographical scenario of the platelet-rich plasma therapy market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is expected to command the largest share of the global platelet-rich plasma therapy market in 2021, followed by Europe and Asia-Pacific.

Key companies operating in the global platelet rich plasma therapy market are Arthrex, Inc. (U.S.), DePuy Synthes Inc. (U.S.), Dr PRP USA LLC (U.S.), EmCyte Corporation (U.S.), Exactech Inc. (U.S.), Global Stem Cells Group, Inc. (U.S.), Celling Biosciences, Inc. (U.S.), Terumo Corporation (Japan), Regen Lab SA (Switzerland), Stryker Corporation (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), and Juventix Regenerative Medical LLC (U.S.).


Scope of the Report
Global Platelet Rich Plasma Therapy Market, by Type

  • Pure Platelet rich Plasma
  • Leukocyte-rich PRP
  • Platelet-rich Fibrin
  • Leukocyte & Platelet rich Fibrin


Global Platelet Rich Plasma Therapy Market, by Application

  • Orthopedics and Traumatology
  • Dermatology and Cosmetology
  • Rheumatology
  • Stomatology and Odontology
  • Ophthalmology
  • Others


Global Platelet Rich Plasma Therapy Market, by End User

  • Hospitals and Clinics
  • Research Institutes


Global Platelet Rich Plasma Therapy Market, by Geography

  • North America


o U.S.

o Canada

  • Europe


o Germany
o France
o U.K.

o Italy
o Spain
o Rest of Europe (RoE)

  • Asia-Pacific (APAC)


o Japan
o China
o India
o Rest of APAC (RoAPAC)

  • Latin America


o Brazil
o Mexico
o Argentina
o Rest of LATAM (RoLATAM)

  • Middle East & Africa